Market Overview

UPDATE: Canaccord Genuity Assumes Buy on Penn Virginia Corporation on Secondary Offering

Related PVA
Penn Virginia Corporation Announces Borrowing Base Increase To $500M And Financial Liquidity In Excess Of $620M
Kite Pharmaceuticals Releases Positive Non-Hodgkin's Lymphoma Result; iKang Healthcare Disappoints

Canaccord Genuity assumed coverage on Penn Virginia Corporation (NYSE: PVA) with a Buy rating and a $8 price target.

Canaccord Genuity said, "We are assuming coverage of PVA with a BUY rating and new (lower) 12-month price target of $8, which takes into account the dilution from the recent offering of common stock. PVA has been successfully transitioning to a liquids-focused company while retaining its leverage to an improvement in natural gas prices."

Penn Virginia Corporation closed at $5.00 on Thursday.

Latest Ratings for PVA

Dec 2014BarclaysMaintainsEqual-weight
Dec 2014Imperial CapitalMaintainsOutperform
Nov 2014Credit SuisseMaintainsOutperform

View More Analyst Ratings for PVA
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (PVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters